Uni Bio Science Group, Ltd.
HHKEX:6900.06
HKD
+0.00
(-4.48%)
ISIN
KYG9198H1406
CUSIP
G9198H140
Return %
Stock
S&P 500
1Y
-51.15
14.20
3Y
16.36
81.12
5Y
-31.91
68.34
Capital Structure
HKD
•
in mil. unless spec.Working Capital
HKD
•
in mil. unless spec.Growth Rates
HKD
•
in mil. unless spec.Semi-annual Revenue
HKD
•
in mil. unless spec.Semi-annual Earnings Per Share
HKD
•
in mil. unless spec.Semi-annual Dividends Per Share
HKD
•
in mil. unless spec.Company Description
- CEO
- Zhi Gang Zhao
- Full Time Employees
- 543
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- No. 20 Science Park East Avenue Hong Kong Hong Kong
- IPO Date
- Nov 12, 2001
- Website
- uni-bioscience.com
- Similar Companies
- Business
- Uni-Bio Science Group Limited (0690.HK) is a Hong Kong-listed investment holding company that researches, develops, manufactures and sells biological and chemical pharmaceutical products to treat human diseases, primarily in the People's Republic of China; it operates through segments including chemical pharmaceutical products, biological pharmaceutical products and pipeline products. The company offers core products such as GeneTime, a prescription biological drug for wound healing; GeneSoft, a therapeutic drug for dry eye syndrome, corneal damage and post-operative healing; Pinup, a voriconazole tablet to treat invasive aspergillosis and fungal infections; Boshutai, a small molecule drug to treat diabetes; and Bogutai (teriparatide injection), a disposable injection pen for osteoporosis treatment; it also provides medical aesthetics solutions including medical-grade dressings and cosmeceuticals, alongside pipeline developments like rhPTH 1-34 (UNI-PTH) for postmenopausal osteoporosis, Uni-GLP (a GLP-1 agent) for Type 2 diabetes and obesity, and advanced platforms in regenerative medicine covering muscular-skeletal, skin, ocular, ENT and stem cell technologies with innovations like ECO-KSFA microprotein superfactory and smart hydrogels. Founded in 2001 and headquartered at Unit 502, 5/F, No. 20 Science Park East Avenue, Hong Kong Science Park, Sha Tin, New Territories, Hong Kong, the company maintains GMP-certified manufacturing facilities in Beijing and Shenzhen, with main R&D in Guangdong province and a focus on target markets including endocrine disorders, ophthalmology, dermatology, orthopedics and medical aesthetics. Recent developments include the China NMPA approval of Bogutai marketing application, boosting orthopedic treatment options; a May 2024 strategic partnership with Great Bay Bio (GBB) and Tigermed's Pebble Accelerator for innovative weight reduction drugs using AI-driven antibody development; a July 2024 alliance with Chongqing Minji Medical Device Co., Ltd. for exclusive distribution and co-development of fibronectin-based Class II medical aesthetic devices targeting over RMB30 million annual revenue; a September 2025 partnership with Kexing Biopharm to accelerate global expansion of Bogutai; a November 2025 strategic shift toward regenerative medicine leadership with industry-academia collaborations, international partnerships and a new bilingual website launch; and robust 2025 interim financials with profit surging to HK$70.9 million amid e-commerce expansion and preparations for Guangdong centralized drug procurement.